A pharmacokinetic evaluation of the addition of Aprepitant to the Cisplatin - Etoposide (CE) treatment of patients with metastatic lung carcinoma (ACE)
- Conditions
- misselijkheid en braken na toedienen cytostatica kuurnausea and vomiting10027656
- Registration Number
- NL-OMON31383
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Subject is at least 18 and no older than 75 years of age
Subject is able and willing to sign the Informed Consent Form prior to screening evaluations
Subject has an indication for treatment with CE regimen
Subject is expected to receive at least 2 cycles of CE regimen
Subject is able to swallow capsules
Documented history of sensitivity/idiosyncrasy to aprepitant capsules or exipients
Relevant history or current condition that might interfere with drug absorption
History or current abuse of drugs, alcohol or solvents
Inability to understand the nature and extent of the trial and the procedures required
Participation in a drug trial within 30 days before the first dose
Febrile illness within 3 days before the first dose
Concomitant use of agents that are known to interfere with aprepitant pharmacokinetics
Abnormal liver or renal function
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method